(RTTNews) - Halozyme Therapeutics (HALO ... of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20, which is Halozyme's ENHANZE drug delivery technology.

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00. Discover outperforming stocks and invest smarter with Top ...

Evotec’s shares in Frankfurt jumped more than 20%. “Just Evotec, Evotec's differentiated biologics continuous manufacturing platform, appears to be a key driver of Halozyme's interest, in our ...